6.1
The committee noted that insertion of a subretinal prosthesis system for retinitis pigmentosa is intended for patients with end‑stage disease who have no useful sight and no other treatment options. It recognised that even minor improvements in vision may help these patients, but it wanted evidence that any changes in metrics of vision result in improvements in quality of life and activities of daily living. These considerations underpinned the specific recommendations about research in section 1.2.